| PRECLINICAL | evidence | Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review. | Tirzepatide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Endocrinology: What You May Have Missed in 2025. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Novel evidence for tirzepatide, a dual GLP-1/GIP receptor agonist, to reduce the motivation for cocaine in rodents. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Brachial Plexopathy Following Rapid Weight Loss from Tirzepatide: A Case Report. | Tirzepatide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Tirzepatide improves angiogenesis after diabetic hindlimb ischemia through Akt/eNOS and ERK1/2 pathways. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Psoriasis flare following tirzepatide initiation in a patient with plaque psoriasis in remission: A case report. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | [Obesity and type 2 diabetes mellitus (Update 2026)]. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. | Tirzepatide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide and tirzepatide for obesity: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Symmetrical drug-related intertriginous and flexural exanthema associated with tirzepatide. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Mental health outcomes in obesity interventions with GLP-1 receptor agonists: is it similar to other obesity interventions? A narrative review with systematic evidence synthesis. | Tirzepatide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | A Case of GLP-1 Receptor Agonist-Induced Dysphoria and Aggression in a Patient With Underlying Major Depressive Disorder. | Zepbound | Mood & anxiety | 2026-05-01 |
| PRECLINICAL | evidence | Commentary on the Risks of Prescription GLP-1 Agonists in Patients on Psychiatric Medications. | Tirzepatide | Mood & anxiety | 2026-05-01 |
| PRECLINICAL | evidence | Pharmacological therapy in the obese patient: is it only a matter of fat loss? | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Tirzepatide and semaglutide: different twins? | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Tirzepatide and Cardiometabolic Effects in Obese Non-diabetic Adults: A Systematic Review, Meta-Analysis, and Narrative Synthesis of Cardiovascular Outcomes. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | A Case of an Invisible Pancreatic Neuroendocrine Tumor Decoded by Endoscopic Ultrasound. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Improvement of Compulsive Shopping on Tirzepatide: A Case Report. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | [Individualizing antihypertensive therapy in diabetes mellitus. Guidelines of the Austrian Diabetes Association (Update 2026)]. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Correction to "Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3". | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study. | Tirzepatide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Addressing Tamoxifen-Associated Weight Gain: Lifestyle and Pharmacotherapy Options. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists and hair loss: An emerging clinical concern. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Tirzepatide Combined With Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnoea Syndrome With Comorbid Obesity: Effects on Weight, Daytime Sleepiness, and Cognitive Performance. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations. | Tirzepatide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure. | Tirzepatide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials. | Tirzepatide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials. | Tirzepatide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control. | Tirzepatide | — | 2026-05-01 |
| PRECLINICAL | evidence | Heart failure in 2025: new insights, therapies, and clinical directions. | Tirzepatide | — | 2026-04-30 |
| PRECLINICAL | evidence | Tirzepatide attenuates doxorubicin-induced cardiotoxicity via mitochondrial function improvement. | Tirzepatide | — | 2026-04-30 |
| PRECLINICAL | evidence | Use of semaglutide and tirzepatide among people with multiple sclerosis. | Tirzepatide | — | 2026-04-29 |
| PRECLINICAL | evidence | The Obesity-OSA-Arrhythmia Axis: Pathophysiological Mechanisms and Translational Therapeutic Targets. | Tirzepatide | — | 2026-04-29 |
| PRECLINICAL | evidence | Blamed but not at fault: Anti-obesity medication adverse effects misidentified as perioperative complications - a comprehensive review and medicolegal warning for anesthesiologists. | Tirzepatide | — | 2026-04-28 |
| PRECLINICAL | evidence | Impact of Tirzepatide on FIB-4 in Patients with Type 2 Diabetes: A Comparison between GLP-1RA-naive and GLP-1RA Switch Initiation in a Retrospective Cohort. | Tirzepatide | — | 2026-04-28 |